Notably, the application of a miR-19a inhibitor effectively mitigated the malignant characteristics of CRC cells, concomitantly leading to the down-regulation of matrix metallopeptidase 9 (MMP-9) and vascular endothelial growth factor C (VEGFC) expression [66]. Here, VEGFC is linked to colorectal carcinoma.